Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Sold by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. reduced its position in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSNFree Report) by 71.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 59,051 shares of the company’s stock after selling 149,382 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned 0.05% of Mersana Therapeutics worth $243,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the stock. Swiss National Bank boosted its holdings in Mersana Therapeutics by 7.6% during the first quarter. Swiss National Bank now owns 135,996 shares of the company’s stock valued at $543,000 after acquiring an additional 9,600 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Mersana Therapeutics by 880.4% in the first quarter. JPMorgan Chase & Co. now owns 309,629 shares of the company’s stock valued at $1,236,000 after acquiring an additional 278,047 shares during the last quarter. Bank of Montreal Can bought a new position in Mersana Therapeutics in the 1st quarter worth approximately $4,665,000. BlackRock Inc. grew its holdings in Mersana Therapeutics by 2.0% during the 1st quarter. BlackRock Inc. now owns 7,626,196 shares of the company’s stock worth $30,427,000 after acquiring an additional 146,967 shares during the period. Finally, Federated Hermes Inc. lifted its position in Mersana Therapeutics by 257.4% in the 1st quarter. Federated Hermes Inc. now owns 723,933 shares of the company’s stock valued at $2,888,000 after acquiring an additional 521,350 shares in the last quarter. 93.45% of the stock is owned by institutional investors and hedge funds.

Mersana Therapeutics Trading Down 1.6 %

Shares of MRSN opened at $1.21 on Monday. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.97 and a quick ratio of 3.97. Mersana Therapeutics, Inc. has a 1 year low of $0.80 and a 1 year high of $9.62. The company has a 50 day simple moving average of $2.51 and a two-hundred day simple moving average of $4.69. The firm has a market cap of $145.82 million, a P/E ratio of -0.59 and a beta of 1.47.

Mersana Therapeutics (NASDAQ:MRSNGet Free Report) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.03). Mersana Therapeutics had a negative net margin of 555.84% and a negative return on equity of 255.91%. The company had revenue of $10.70 million for the quarter, compared to analysts’ expectations of $12.93 million. The firm’s quarterly revenue was up 148.8% on a year-over-year basis. On average, equities analysts expect that Mersana Therapeutics, Inc. will post -1.43 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. BTIG Research cut shares of Mersana Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, July 27th. Truist Financial reiterated a “hold” rating on shares of Mersana Therapeutics in a research report on Thursday, July 27th. Wedbush reissued a “neutral” rating and set a $2.00 price target on shares of Mersana Therapeutics in a research report on Tuesday, August 8th. Citigroup lowered shares of Mersana Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, July 27th. Finally, JPMorgan Chase & Co. cut shares of Mersana Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Thursday, July 27th. One research analyst has rated the stock with a sell rating and six have given a hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $8.57.

View Our Latest Stock Report on Mersana Therapeutics

Mersana Therapeutics Company Profile

(Free Report)

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has a research and development collaborations with Janssen Biotech, Inc and Merck KGaA, as well as collaboration agreement with Asana BioSciences, LLC for the development of ADC product candidates.

Featured Stories

Want to see what other hedge funds are holding MRSN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mersana Therapeutics, Inc. (NASDAQ:MRSNFree Report).

Institutional Ownership by Quarter for Mersana Therapeutics (NASDAQ:MRSN)

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.